Form 4: Apellis Pharmaceuticals Director Sinclair Dunlop Sells Shares

Director Sinclair Dunlop reports selling shares of Apellis Pharmaceuticals through a non-Rule 10b5-1 trading plan.

Summary

• Director Sinclair Dunlop reported the sale of Apellis Pharmaceuticals, Inc. common stock on September 16, 2024.
• The sales were executed under a pre-arranged non-Rule 10b5-1 trading plan adopted by Epidarex Capital I LP on March 2, 2024.
• A total of 29,476 shares were sold at a weighted average price of $36.09, with individual transactions ranging from $35.52 to $36.46.
• An additional 7,524 shares were sold at a weighted average price of $36.79, with individual transactions ranging from $36.55 to $37.21.
• Following the reported transactions, Dunlop directly owns 147,526 shares, including 6,885 shares issuable under unvested restricted stock units.
• Dunlop also has indirect ownership of 100,000 shares through Epidarex Capital I, LP.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, reporting the sale of shares by a company director. It doesn't inherently convey positive or negative sentiment, but the market may interpret insider sales as slightly negative.

Industry Context

Sales by company insiders are a common occurrence and are often scrutinized by investors for insights into management's perspective on the company's valuation and future prospects. However, sales under a pre-arranged 10b5-1 trading plan are less likely to be indicative of management's current sentiment, as these plans are often established well in advance.

Stakeholder Impact

• The sale of shares by a director could potentially influence investor sentiment, although the existence of a pre-arranged trading plan mitigates this concern.

Key Dates